Biotech Values

[jq1234]

EXEL - IMO the article is incomplete since it does not include the impact of competition to 184. Given the success of MDV3100 (albeit at a different stage of the disease) the CRPC market is now getting crowded. 184 will have to differentiate itself and prove to be better than drugs like 3100 that will already be in the market by the time the 307 trial concludes.

If XL184 succeeds in 306/307 trial - big IF - it is differentiated from other treatments in CRPC space. 306/307 trials include pretty much only docetaxel, Zytiga/MDV3100 failure patients - I would assume Provenge failure patients as well. XL184 is basically competing against Alpharadin directly. Alpharadin data were impressive, but it is radiopharmaceutical, I am not sure its market potential vs oral drug. MDV3100 has similar mechanism of action to Zytiga.